$ABUS
Arbutus Biopharma Corp Stock $abus

$abus Overview Financials Valuation SEC Filings Company Website

2023 Q4 Form 10-Q Financial Statement

#000144702823000090 Filed on November 07, 2023

Income Statement

Concept	2023 Q4	2023 Q3
Revenue	$2.145M	$4.658M
YoY Change	-65.65%	-21.74%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$5.101M	$5.840M
YoY Change	20.05%	67.19%
% of Gross Profit
Research & Development	$17.56M	$20.17M
YoY Change	-23.47%	0.57%
% of Gross Profit
Depreciation & Amortization	$359.0K	$370.0K
YoY Change	16.94%	7.87%
% of Gross Profit
Operating Expenses	$22.89M	$26.22M
YoY Change	-20.53%	10.32%
Operating Profit		-$21.56M
YoY Change		21.04%
Interest Expense	$1.435M	$46.00K
YoY Change	127.78%	-89.28%
% of Operating Profit
Other Income/Expense, Net		$1.454M
YoY Change		495.9%
Pretax Income	-$19.31M	-$20.10M
YoY Change	-11.95%	14.44%
Income Tax	$0.00	$0.00
% Of Pretax Income
Net Earnings	-$19.31M	-$20.10M
YoY Change	-11.95%	14.44%
Net Earnings / Revenue	-900.33%	-431.6%
Basic Earnings Per Share		-$0.12
Diluted Earnings Per Share	-$0.11	-$0.12
COMMON SHARES
Basic Shares Outstanding	167.7M shares	167.6M shares
Diluted Shares Outstanding		167.5M shares

Balance Sheet

Concept	2023 Q4	2023 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments	$126.0M	$134.2M
YoY Change	-14.23%	-0.4%
Cash & Equivalents	$26.29M	$17.53M
Short-Term Investments	$99.72M	$116.6M
Other Short-Term Assets	$4.248M	$5.300M
YoY Change	47.81%	15.64%
Inventory
Prepaid Expenses
Receivables	$1.776M	$2.171M
Other Receivables	$0.00	$0.00
Total Short-Term Assets	$132.0M	$141.6M
YoY Change	-12.65%	0.33%
LONG-TERM ASSETS
Property, Plant & Equipment	$4.674M	$5.033M
YoY Change	-7.81%	-3.97%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments	$0.00	$0.00
YoY Change
Other Assets	$0.00	$3.000K
YoY Change	-100.0%	-98.2%
Total Long-Term Assets	$12.37M	$17.03M
YoY Change	-72.06%	-72.82%
TOTAL ASSETS
Total Short-Term Assets	$132.0M	$141.6M
Total Long-Term Assets	$12.37M	$17.03M
Total Assets	$144.4M	$158.6M
YoY Change	-26.11%	-22.16%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$3.223M	$2.300M
YoY Change	-8.44%	163.76%
Accrued Expenses	$7.473M	$8.000M
YoY Change	-41.98%	-31.95%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$22.49M	$22.32M
YoY Change	-31.56%	-18.84%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00
YoY Change
Other Long-Term Liabilities	$15.90M	$17.00M
YoY Change	-38.17%	-44.77%
Total Long-Term Liabilities	$15.90M	$17.00M
YoY Change	-38.17%	-44.77%
TOTAL LIABILITIES
Total Short-Term Liabilities	$22.49M	$22.32M
Total Long-Term Liabilities	$15.90M	$17.00M
Total Liabilities	$38.38M	$39.30M
YoY Change	-34.46%	-32.56%
SHAREHOLDERS EQUITY
Retained Earnings	-$1.277B	-$1.257B
YoY Change	6.05%	6.39%
Common Stock	$1.350B	$1.346B
YoY Change	2.36%	2.93%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$106.0M	$119.3M
YoY Change
Total Liabilities & Shareholders Equity	$144.4M	$158.6M
YoY Change	-26.11%	-22.16%

Cashflow Statement

Concept	2023 Q4	2023 Q3
OPERATING ACTIVITIES
Net Income	-$19.31M	-$20.10M
YoY Change	-11.95%	14.44%
Depreciation, Depletion And Amortization	$359.0K	$370.0K
YoY Change	16.94%	7.87%
Cash From Operating Activities	-$17.29M	-$21.78M
YoY Change	1.78%	16.52%
INVESTING ACTIVITIES
Capital Expenditures	-$2.000K	$30.00K
YoY Change	-101.49%	-132.97%
Acquisitions
YoY Change
Other Investing Activities	$22.22M	$10.46M
YoY Change	73.42%	-176.65%
Cash From Investing Activities	$22.23M	$10.43M
YoY Change	75.25%	-175.92%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	3.807M	1.680M
YoY Change	-65.65%	-81.6%
NET CHANGE
Cash From Operating Activities	-17.29M	-21.78M
Cash From Investing Activities	22.23M	10.43M
Cash From Financing Activities	3.807M	1.680M
Net Change In Cash	8.740M	-9.670M
YoY Change	28.98%	-58.49%
FREE CASH FLOW
Cash From Operating Activities	-$17.29M	-$21.78M
Capital Expenditures	-$2.000K	$30.00K
Free Cash Flow	-$17.29M	-$21.81M
YoY Change	0.97%	17.25%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2023Q3	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	3000	usd
CY2022Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	103000	usd
CY2023Q3	us-gaap	Assets Assets	158641000	usd
CY2022Q4	us-gaap	Assets Assets	195419000	usd
CY2023Q3	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	9806000	usd
CY2022Q4	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	16029000	usd
CY2023Q3	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	12106000	usd
CY2022Q4	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	16456000	usd
CY2023Q3	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	412000	usd
CY2022Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	372000	usd
CY2023Q3	us-gaap	Liabilities Current LiabilitiesCurrent	22324000	usd
CY2022Q4	us-gaap	Liabilities Current LiabilitiesCurrent	32857000	usd
CY2023Q3	abus	Liability Related To Sale Of Future Royalties Noncurrent LiabilityRelatedToSaleOfFutureRoyaltiesNoncurrent	8110000	usd
CY2022Q4	abus	Liability Related To Sale Of Future Royalties Noncurrent LiabilityRelatedToSaleOfFutureRoyaltiesNoncurrent	10365000	usd
CY2023Q3	us-gaap	Deferred Revenue Noncurrent DeferredRevenueNoncurrent	0	usd
CY2022Q4	us-gaap	Deferred Revenue Noncurrent DeferredRevenueNoncurrent	5999000	usd
CY2023Q3	us-gaap	Business Combination Contingent Consideration Liability Noncurrent BusinessCombinationContingentConsiderationLiabilityNoncurrent	7373000	usd
CY2022Q4	us-gaap	Business Combination Contingent Consideration Liability Noncurrent BusinessCombinationContingentConsiderationLiabilityNoncurrent	7531000	usd
CY2023Q3	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	1497000	usd
CY2022Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	1815000	usd
CY2023Q3	us-gaap	Liabilities Liabilities	39304000	usd
CY2022Q4	us-gaap	Liabilities Liabilities	58567000	usd
CY2022Q4	us-gaap	Liabilities Liabilities	58567000	usd
CY2022Q4	us-gaap	Liabilities Liabilities	58567000	usd
CY2022Q4	us-gaap	Common Stock Value CommonStockValue	1318737000	usd
CY2022Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	72406000	usd
CY2023Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-1257340000	usd
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-1203803000	usd
CY2023Q3	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-48884000	usd
CY2022Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-50488000	usd
CY2023Q3	us-gaap	Stockholders Equity StockholdersEquity	119337000	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	136852000	usd
CY2023Q3	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	158641000	usd
CY2022Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	195419000	usd
CY2023Q3	us-gaap	Revenues Revenues	4658000	usd
CY2022Q3	us-gaap	Revenues Revenues	5952000	usd
	us-gaap	Revenues Revenues	15996000	usd
CY2023Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	20169000	usd
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	61459000	usd
CY2022Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	3493000	usd
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	17374000	usd
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	13585000	usd
CY2023Q3	abus	Increase Decrease In Fair Value Of Contingent Consideration Liability IncreaseDecreaseInFairValueOfContingentConsiderationLiability	205000	usd
CY2022Q3	abus	Increase Decrease In Fair Value Of Contingent Consideration Liability IncreaseDecreaseInFairValueOfContingentConsiderationLiability	215000	usd
	abus	Increase Decrease In Fair Value Of Contingent Consideration Liability IncreaseDecreaseInFairValueOfContingentConsiderationLiability	-158000	usd
	abus	Increase Decrease In Fair Value Of Contingent Consideration Liability IncreaseDecreaseInFairValueOfContingentConsiderationLiability	624000	usd
CY2023Q3	us-gaap	Interest Expense InterestExpense	46000	usd
CY2022Q3	us-gaap	Interest Expense InterestExpense	429000	usd
	us-gaap	Interest Expense InterestExpense	415000	usd
	us-gaap	Interest Expense InterestExpense	1417000	usd
CY2023Q3	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-20104000	usd
CY2022Q3	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-17567000	usd
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-53537000	usd
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-43080000	usd
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.32
CY2023Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	167512708	shares
CY2023Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	167512708	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	165085243	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	165085243	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	149385999	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	149385999	shares
CY2023Q3	us-gaap	Debt Securities Available For Sale Unrealized Gain Loss DebtSecuritiesAvailableForSaleUnrealizedGainLoss	584000	usd
CY2022Q3	us-gaap	Debt Securities Available For Sale Unrealized Gain Loss DebtSecuritiesAvailableForSaleUnrealizedGainLoss	-907000	usd
	us-gaap	Debt Securities Available For Sale Unrealized Gain Loss DebtSecuritiesAvailableForSaleUnrealizedGainLoss	1604000	usd
	us-gaap	Debt Securities Available For Sale Unrealized Gain Loss DebtSecuritiesAvailableForSaleUnrealizedGainLoss	-2669000	usd
CY2023Q3	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-19520000	usd
CY2023Q3	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	167695247	shares
CY2023Q3	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	167695247	shares
CY2022Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	157455363	shares
CY2022Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	157455363	shares
CY2023Q3	us-gaap	Common Stock Value CommonStockValue	1346015000	usd
CY2023Q3	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	79546000	usd
CY2023Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	usd
CY2022Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	usd
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	usd
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	4444000	usd
CY2023Q3	us-gaap	Net Income Loss NetIncomeLoss	-20104000	usd
CY2022Q3	us-gaap	Net Income Loss NetIncomeLoss	-17567000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-53537000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-47524000	usd
CY2023Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.12
CY2023Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.12
CY2022Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.12
CY2022Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.12
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.32
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.32
CY2022Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	150995191	shares
CY2022Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	150995191	shares
CY2022Q3	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-18474000	usd
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-51933000	usd
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-50193000	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	136852000	usd
CY2023Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	2131000	usd
CY2023Q1	abus	Stock Issued During Period Value New Issues Open Market Sale Agreement StockIssuedDuringPeriodValueNewIssuesOpenMarketSaleAgreement	19862000	usd
CY2023Q1	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	259000	usd
CY2023Q1	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	296000	usd
CY2023Q1	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	854000	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-16339000	usd
CY2023Q1	us-gaap	Stockholders Equity StockholdersEquity	143915000	usd
CY2023Q2	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	2964000	usd
CY2023Q2	abus	Stock Issued During Period Value New Issues Open Market Sale Agreement StockIssuedDuringPeriodValueNewIssuesOpenMarketSaleAgreement	4742000	usd
CY2023Q2	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	166000	usd
CY2023Q2	us-gaap	Net Income Loss NetIncomeLoss	-17094000	usd
CY2023Q2	us-gaap	Stockholders Equity StockholdersEquity	134693000	usd
CY2023Q3	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	2483000	usd
CY2023Q3	abus	Stock Issued During Period Value New Issues Open Market Sale Agreement StockIssuedDuringPeriodValueNewIssuesOpenMarketSaleAgreement	1396000	usd
CY2022Q1	abus	Adjustmentsto Additional Paidin Capital Certain Fair Value Adjustmentsto Liability Stock Option Awards AdjustmentstoAdditionalPaidinCapitalCertainFairValueAdjustmentstoLiabilityStockOptionAwards	21000	usd
CY2022Q1	abus	Stock Issued During Period Value New Issues Open Market Sale Agreement StockIssuedDuringPeriodValueNewIssuesOpenMarketSaleAgreement	268000	usd
CY2022Q1	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	8000	usd
CY2022Q1	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	236000	usd
CY2022Q1	abus	Stock Issued During Period Value New Issues Share Purchase Agreement StockIssuedDuringPeriodValueNewIssuesSharePurchaseAgreement	10973000	usd
CY2022Q1	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	-1071000	usd
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	-15765000	usd
CY2022Q1	us-gaap	Stockholders Equity StockholdersEquity	165845000	usd
CY2022Q2	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	2064000	usd
CY2022Q2	abus	Adjustmentsto Additional Paidin Capital Certain Fair Value Adjustmentsto Liability Stock Option Awards AdjustmentstoAdditionalPaidinCapitalCertainFairValueAdjustmentstoLiabilityStockOptionAwards	3000	usd
CY2022Q2	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	113000	usd
CY2022Q2	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	-691000	usd
CY2022Q2	us-gaap	Net Income Loss NetIncomeLoss	-14192000	usd
CY2022Q2	us-gaap	Stockholders Equity StockholdersEquity	153142000	usd
CY2022Q3	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	1715000	usd
CY2022Q3	abus	Adjustmentsto Additional Paidin Capital Certain Fair Value Adjustmentsto Liability Stock Option Awards AdjustmentstoAdditionalPaidinCapitalCertainFairValueAdjustmentstoLiabilityStockOptionAwards	2000	usd
CY2022Q3	abus	Stock Issued During Period Value New Issues Open Market Sale Agreement StockIssuedDuringPeriodValueNewIssuesOpenMarketSaleAgreement	8973000	usd
CY2022Q3	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	159000	usd
CY2022Q3	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	-907000	usd
CY2022Q3	us-gaap	Net Income Loss NetIncomeLoss	-17567000	usd
CY2022Q3	us-gaap	Stockholders Equity StockholdersEquity	145517000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-53537000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-47524000	usd
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	1045000	usd
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	1120000	usd
	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	20000	usd
	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	20000	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	7578000	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	5515000	usd
	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1	-158000	usd
	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1	624000	usd
	abus	Non Cash Royalty Revenue Related To Sale Of Future Royalties NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties	2667000	usd
	abus	Non Cash Royalty Revenue Related To Sale Of Future Royalties NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties	5393000	usd
	abus	Non Cash Interest Expense Related To Sale Of Future Royalties NonCashInterestExpenseRelatedToSaleOfFutureRoyalties	412000	usd
	abus	Non Cash Interest Expense Related To Sale Of Future Royalties NonCashInterestExpenseRelatedToSaleOfFutureRoyalties	1413000	usd
	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	1577000	usd
	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	-170000	usd
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	819000	usd
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	936000	usd
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	2040000	usd
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-27000	usd
	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-6223000	usd
	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	1456000	usd
	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	-10349000	usd
	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	25463000	usd
	us-gaap	Increase Decrease In Other Operating Liabilities IncreaseDecreaseInOtherOperatingLiabilities	-289000	usd
	us-gaap	Increase Decrease In Other Operating Liabilities IncreaseDecreaseInOtherOperatingLiabilities	-281000	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-68644000	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-18366000	usd
	us-gaap	Payments To Acquire Investments PaymentsToAcquireInvestments	56490000	usd
	us-gaap	Payments To Acquire Investments PaymentsToAcquireInvestments	117266000	usd
	us-gaap	Proceeds From Sale Maturity And Collections Of Investments ProceedsFromSaleMaturityAndCollectionsOfInvestments	86026000	usd
	us-gaap	Proceeds From Sale Maturity And Collections Of Investments ProceedsFromSaleMaturityAndCollectionsOfInvestments	30000000	usd
	us-gaap	Proceeds From Sale Of Property Plant And Equipment ProceedsFromSaleOfPropertyPlantAndEquipment	20000	usd
	us-gaap	Proceeds From Sale Of Property Plant And Equipment ProceedsFromSaleOfPropertyPlantAndEquipment	20000	usd
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	1008000	usd
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	378000	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	28548000	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-87624000	usd
	abus	Proceeds From Issuance Of Common Stock Share Purchase Agreement ProceedsFromIssuanceOfCommonStockSharePurchaseAgreement	0	usd
	abus	Proceeds From Issuance Of Common Stock Share Purchase Agreement ProceedsFromIssuanceOfCommonStockSharePurchaseAgreement	10973000	usd
	abus	Proceeds From Issuance Of Common Stock Open Market Sale Agreement ProceedsFromIssuanceOfCommonStockOpenMarketSaleAgreement	26000000	usd
	abus	Proceeds From Issuance Of Common Stock Open Market Sale Agreement ProceedsFromIssuanceOfCommonStockOpenMarketSaleAgreement	9241000	usd
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	259000	usd
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	121000	usd
	us-gaap	Proceeds From Stock Plans ProceedsFromStockPlans	581000	usd
	us-gaap	Proceeds From Stock Plans ProceedsFromStockPlans	395000	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	26840000	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	20730000	usd
	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	11000	usd
	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	-18000	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-13245000	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-85278000	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	30776000	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	109282000	usd
CY2023Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	17531000	usd
CY2022Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	24004000	usd
	us-gaap	Nature Of Operations NatureOfOperations	Nature of business and future operations<div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Description of the Business</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Arbutus Biopharma Corporation (“Arbutus” or the “Company”) is a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop a functional cure for patients with chronic hepatitis B virus (“cHBV”). The Company believes the key to success in developing a functional cure involves suppressing HBV DNA, reducing surface antigen and boosting HBV-specific immune response. The Company’s pipeline of internally developed, proprietary compounds includes an RNAi therapeutic, imdusiran (AB-729), and an oral PD-L1 inhibitor, AB-101. Imdusiran has generated meaningful clinical data demonstrating an impact on both surface antigen reduction and reawakening of the HBV-specific immune response. Imdusiran is currently in two Phase 2a combination clinical trials. AB-101 is currently being evaluated in a Phase 1a/1b clinical trial. Additionally, the Company has identified compounds in its internal PD-L1 portfolio that could be used in oncology indications. </span></div><div style="text-align:justify"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Liquidity</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At September 30, 2023, the Company had an aggregate of $144.7 million in cash, cash equivalents and investments in marketable securities. The Company had no outstanding debt as of September 30, 2023. The Company believes it has sufficient cash resources to fund its operations for at least the next 12 months. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The success of the Company is dependent on obtaining the necessary regulatory approvals to bring its products to market and achieve profitable operations. The Company’s research and development activities and the commercialization of its products are dependent on its ability to successfully complete these activities and to obtain adequate financing through a combination of financing activities and operations. It is not possible to predict either the outcome of the Company’s existing or future research and development programs or the Company’s ability to continue to fund these programs in the future.</span></div>
CY2023Q3	us-gaap	Investments And Cash InvestmentsAndCash	144700000	usd
CY2023Q3	us-gaap	Long Term Debt LongTermDebt	0	usd
CY2023Q3	abus	Wholly Owned Subsidiaries Includedin Financial Statements WhollyOwnedSubsidiariesIncludedinFinancialStatements	1	subsidiary
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	15900000	shares
CY2023Q3	us-gaap	Business Combination Contingent Consideration Liability Noncurrent BusinessCombinationContingentConsiderationLiabilityNoncurrent	7400000	usd
	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1	-200000	usd
CY2022Q4	us-gaap	Business Combination Contingent Consideration Liability Noncurrent BusinessCombinationContingentConsiderationLiabilityNoncurrent	7531000	usd
	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1	-158000	usd
CY2023Q3	us-gaap	Business Combination Contingent Consideration Liability Noncurrent BusinessCombinationContingentConsiderationLiabilityNoncurrent	7373000	usd
CY2021Q4	us-gaap	Business Combination Contingent Consideration Liability Noncurrent BusinessCombinationContingentConsiderationLiabilityNoncurrent	5298000	usd
	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1	624000	usd
CY2022Q3	us-gaap	Business Combination Contingent Consideration Liability Noncurrent BusinessCombinationContingentConsiderationLiabilityNoncurrent	5922000	usd
CY2023Q3	us-gaap	Debt Securities Available For Sale Unrealized Loss Position Number Of Positions DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions	40	numberofsegments
CY2022Q4	us-gaap	Debt Securities Available For Sale Unrealized Loss Position Number Of Positions DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions	53	numberofsegments
CY2022Q4	us-gaap	Accrued Investment Income Receivable AccruedInvestmentIncomeReceivable	600000	usd
CY2023Q3	us-gaap	Accrued Investment Income Receivable AccruedInvestmentIncomeReceivable	600000	usd
	us-gaap	Debt Securities Realized Gain Loss DebtSecuritiesRealizedGainLoss	100000	usd
CY2022Q3	us-gaap	Debt Securities Realized Gain Loss DebtSecuritiesRealizedGainLoss	100000	usd
CY2023Q3	us-gaap	Debt Securities Realized Gain Loss DebtSecuritiesRealizedGainLoss	100000	usd
	us-gaap	Debt Securities Realized Gain Loss DebtSecuritiesRealizedGainLoss	100000	usd
CY2023Q3	us-gaap	Equity Method Investments EquityMethodInvestments	0	usd
	us-gaap	Premiums Earned Net PremiumsEarnedNet	4100000	usd
CY2023Q3	us-gaap	Accounts Payable Trade Current AccountsPayableTradeCurrent	2260000	usd
CY2022Q4	us-gaap	Accounts Payable Trade Current AccountsPayableTradeCurrent	3520000	usd
CY2023Q3	abus	Accrued Research And Development AccruedResearchAndDevelopment	4210000	usd
CY2022Q4	abus	Accrued Research And Development AccruedResearchAndDevelopment	8261000	usd
CY2023Q3	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	691000	usd
CY2022Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	512000	usd
CY2023Q3	abus	Accrued Payroll Current AccruedPayrollCurrent	2645000	usd
CY2022Q4	abus	Accrued Payroll Current AccruedPayrollCurrent	3730000	usd
CY2023Q3	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	0	usd
CY2022Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	6000	usd
CY2023Q3	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	9806000	usd
CY2022Q4	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	16029000	usd
CY2022Q4	abus	Liability Related To Sale Of Future Royalties Noncurrent LiabilityRelatedToSaleOfFutureRoyaltiesNoncurrent	10365000	usd
CY2021Q4	abus	Liability Related To Sale Of Future Royalties Noncurrent LiabilityRelatedToSaleOfFutureRoyaltiesNoncurrent	16296000	usd
	abus	Liability From Sale Of Future Royalties Non Cash Royalty Income LiabilityFromSaleOfFutureRoyaltiesNonCashRoyaltyIncome	2667000	usd
	abus	Liability From Sale Of Future Royalties Non Cash Royalty Income LiabilityFromSaleOfFutureRoyaltiesNonCashRoyaltyIncome	5393000	usd
	abus	Liability From Sale Of Future Royalties Non Cash Interest Expense LiabilityFromSaleOfFutureRoyaltiesNonCashInterestExpense	412000	usd
	abus	Liability From Sale Of Future Royalties Non Cash Interest Expense LiabilityFromSaleOfFutureRoyaltiesNonCashInterestExpense	1413000	usd
CY2023Q3	abus	Liability Related To Sale Of Future Royalties Noncurrent LiabilityRelatedToSaleOfFutureRoyaltiesNoncurrent	8110000	usd
CY2022Q3	abus	Liability Related To Sale Of Future Royalties Noncurrent LiabilityRelatedToSaleOfFutureRoyaltiesNoncurrent	12316000	usd
CY2023Q3	us-gaap	Contract With Customer Liability ContractWithCustomerLiability	12106000	usd
CY2023Q3	abus	Royalty Entitlements RoyaltyEntitlements	2	product
CY2023Q3	us-gaap	Revenues Revenues	4658000	usd
CY2022Q3	us-gaap	Revenues Revenues	5952000	usd
	us-gaap	Revenues Revenues	15996000	usd
	us-gaap	Revenues Revenues	32774000	usd
CY2023Q3	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	1164000	shares
CY2023Q3	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	2.25
CY2022Q3	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	2.37
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	2.78
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	2.77
CY2023Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod	0	shares
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod	0	shares
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod	1344550	shares
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod	0	shares
CY2023Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue	2.90
CY2022Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue	0
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	7578000	usd
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	5515000	usd
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Award Vesting Period1 ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1	P3Y

Files In Submission

Name	View Source	Status
abus-20230930_cal.xml	Edgar Link	unprocessable
abus-20230930_lab.xml	Edgar Link	unprocessable
abus-20230930_def.xml	Edgar Link	unprocessable
0001447028-23-000090-index-headers.html	Edgar Link	pending
0001447028-23-000090-index.html	Edgar Link	pending
0001447028-23-000090.txt	Edgar Link	pending
0001447028-23-000090-xbrl.zip	Edgar Link	pending
a2023-q310xqex311.htm	Edgar Link	pending
a2023-q310xqex312.htm	Edgar Link	pending
a2023-q310xqex321.htm	Edgar Link	pending
a2023-q310xqex322.htm	Edgar Link	pending
abus-20230930.htm	Edgar Link	pending
abus-20230930.xsd	Edgar Link	pending
abus-20230930_g1.jpg	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
abus-20230930_htm.xml	Edgar Link	completed
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
abus-20230930_pre.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$ABUS
Arbutus Biopharma Corp Stock $abus

2023 Q4 Form 10-Q Financial Statement

#000144702823000090 Filed on November 07, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$ABUS Arbutus Biopharma Corp Stock $abus

2023 Q4 Form 10-Q Financial Statement

#000144702823000090 Filed on November 07, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$ABUS
Arbutus Biopharma Corp Stock $abus